Dicerna Pharmaceuticals Inc. (DRNA) is one of the best performing stocks in the health care sector for companies listed on the New York Stock Exchange or NASDAQ exchange shortly after the opening bell on September 22. Shares of DRNA have climbed 3.53% about 30 minutes into the session to $4.22 after closing the day prior at $4.08. It’s early, but the stock has traded as high as $4.29 and as low as $4.15 so far. Today’s quick advance has come with about 27,468 shares changing hands, compared to an average 30-day volume of 217,190 for Dicerna Pharmaceuticals Inc.. The price is currently below the 30-day volume weighted average price of $4.25 for DRNA.
The share appreciation gives the company a market capitalization of $84.67 million based upon 20.75 million shares outstanding. It also means that DRNA has a price-to-book ratio of 1.3:1 and a price-to-earnings ratio of :1.
In the past 52 weeks, shares of DRNA have traded as low as $2.69 and as high as $15.93. Technical traders will take note that at $4.22, shares of DRNA are trading below their 200-day MA at $5.36 and above their 50-day MA at $3.34. Technical analysts pay close attention to these key moving averages because they often serve as technical support and resistance levels and because a move through or holding above them is typically regarded as bullish.
Who is DRNA?
Dicerna Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The company’s 48 employees are led by CEO Douglas M. Fambrough from the corporate headquarters at 87 Cambridgepark Drive.
For more information on DRNA and other companies trading on the major exchanges, as well as the over the counter markets, or to be considered for contributing content for our distribution network, visit FinancialPress.com today.
All data provided by QuoteMedia, with stock data accurate as of 9:30 AM ET. FinancialPress.com is not responsible for inaccuracies in third-party supplied information.
FinancialPress.com is a leading publisher of market and investment news, commentary, proprietary research and videos from seasoned journalists, analysts and contributors covering the financial markets and global economies. Leveraging our extensive distribution network and social media presence, we have cultivated a valuable audience of engaged market enthusiasts, which in turn delivers a variety of unique opportunities for industry partnerships, corporate communications, market exposure and investment. A complete disclaimer can be viewed here.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of FinancialPress.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://financialpress.com/legal-disclaimer/.